The National Institute of Health envisions a plan for managing tuberculosis in the 21st century. Included in this proposal is targeting host proteins as an add-on therapy to antibiotics. Infectious disease biologists are focusing on this strategy and it is a topic of active research. Recently, a multinational research team…
List view / Grid view
Filter the results
A study in older mice with type 2 diabetes revealed a tuberculosis vaccine elicited a strong immune response, making it a promising candidate for the condition.
Cryogenic electron microscopy revealed that the vitamin B12 transporter on Mycobacterium tuberculosis acts like a non-selective sluice, transporting both the vitamin and antibiotics.
More research into tuberculosis is now possible with the development of an optimisied mouse model that exhibits the same blood immune response to Mycobacterium tuberculosis infection as humans.
A new discovery could lead to the development of a drug for untreatable strains of TB, which can target uptake of the very amino acid that enables the bacteria to spread within the body.
New gene mutation discovery could lead to more rapid and effective therapies for tuberculosis.
Australian researchers have demonstrated the success of a novel TB vaccine in mice, which could provide another treatment option for the disease.
A gene signature in the bloodstream could reveal whether someone is going to develop active tuberculosis (TB) disease months before symptoms begin.
The mechanism our immune cells use to clear bacterial infections like tuberculosis might also be implicated in Parkinson's disease...
Researchers from the Cornell University College of Veterinary Medicine, New York, have discovered a key metabolic mechanism in Mycobacterium tuberculosis (Mtb) bacteria, which presents as a novel drug target for potentially treating tuberculosis.
The collaboration will provide MSc students with industry-relevant learning tools and pharma with a new pipeline of candidate compounds.
Investigators at Dartmouth's Geisel School of Medicine announced that two new studies of DAR-901, their investigational vaccine against tuberculosis (TB), have moved it to the forefront of new vaccines in development for global control of this deadly infectious disease.